` ZVSA (Zyversa Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

Z
ZVSA
vs
S&P 500

Over the past 12 months, ZVSA has underperformed S&P 500, delivering a return of -87% compared to the S&P 500's +14% growth.

Stocks Performance
ZVSA vs S&P 500

Loading
ZVSA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ZVSA vs S&P 500

Loading
ZVSA
S&P 500
Difference
www.alphaspread.com

Performance By Year
ZVSA vs S&P 500

Loading
ZVSA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Zyversa Therapeutics Inc vs Peers

S&P 500
ZVSA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Zyversa Therapeutics Inc
Glance View

Market Cap
1.2m USD
Industry
Biotechnology

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida. The company went IPO on 2021-12-21. The firm is focused on leveraging advanced technologies to develop drugs for patients with renal or inflammatory diseases. The Company’s development pipeline includes renal drug candidate, namely VAR 200, (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. The firm's development pipeline also includes anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its phase 2a renal product candidate, VAR 200, which mediates removal of excess intracellular lipids that contribute to kidney damage leading to end-stage renal disease.

ZVSA Intrinsic Value
0.189 USD
Undervaluation 24%
Intrinsic Value
Price
Z
Back to Top